Kanika Jhanji, Zaitoon Shivji, Marion Lazaj, Lysa Boisse Lomax, Gavin P. Winston, Garima Shukla
{"title":"Quality of life and cannabis use among patients with drug-resistant epilepsy—An observational study from a Canadian tertiary care referral center","authors":"Kanika Jhanji, Zaitoon Shivji, Marion Lazaj, Lysa Boisse Lomax, Gavin P. Winston, Garima Shukla","doi":"10.1002/epd2.20276","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objective</h3>\n \n <p>Very few publications have reported the impact of artisanal cannabis use on overall quality of life among people with drug-resistant epilepsy. This study aimed to evaluate the association of artisanal cannabis use among adults with drug-resistant epilepsy with quality of life, and to determine if an association exists between Quality-of-Life in Epilepsy Inventory-31 (QOLIE-31) ‘T scores’ and different clinical variables.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>This study included patients admitted to a Canadian tertiary care epilepsy center as part of a larger study. These patients were confirmed to have drug-resistant epilepsy by an epileptologist at the Ambulatory Epilepsy Clinic. Patients were categorized into cannabis users (CAN group) (<i>n</i> = 25) and Non-cannabis users (Non-CAN group) (<i>n</i> = 21). Data was collected on RedCap® for epilepsy and cannabis use details. These were analyzed for an association using a binary multivariable logistic regression model between QOLIE-31 ‘T scores’ and age, sex, epilepsy duration, age at initiation of use, duration of cannabis use and psychiatric related comorbidity for all patients. Additionally, different ‘T subscores’ of the questionnaire were compared between the CAN group and Non-CAN group.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>A statistically significant difference between the CAN group and Non-CAN group for the T subscore ‘energy and fatigue’ (<i>p</i> = .004) was found, with the CAN group scoring higher. However, for the ‘overall T score’ between the two groups there was no statically significant difference (<i>p</i> = .11). Additionally, a significant negative correlation between ‘overall T score’ and cannabis use disorder (<i>p</i> = .032) was found.</p>\n </section>\n \n <section>\n \n <h3> Significance</h3>\n \n <p>This study provides new data on association of quality of life in epilepsy with cannabis use and can serve as a foundation for larger future studies to better assess this association.</p>\n </section>\n </div>","PeriodicalId":50508,"journal":{"name":"Epileptic Disorders","volume":"26 6","pages":"779-786"},"PeriodicalIF":1.9000,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/epd2.20276","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Epileptic Disorders","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/epd2.20276","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Objective
Very few publications have reported the impact of artisanal cannabis use on overall quality of life among people with drug-resistant epilepsy. This study aimed to evaluate the association of artisanal cannabis use among adults with drug-resistant epilepsy with quality of life, and to determine if an association exists between Quality-of-Life in Epilepsy Inventory-31 (QOLIE-31) ‘T scores’ and different clinical variables.
Methods
This study included patients admitted to a Canadian tertiary care epilepsy center as part of a larger study. These patients were confirmed to have drug-resistant epilepsy by an epileptologist at the Ambulatory Epilepsy Clinic. Patients were categorized into cannabis users (CAN group) (n = 25) and Non-cannabis users (Non-CAN group) (n = 21). Data was collected on RedCap® for epilepsy and cannabis use details. These were analyzed for an association using a binary multivariable logistic regression model between QOLIE-31 ‘T scores’ and age, sex, epilepsy duration, age at initiation of use, duration of cannabis use and psychiatric related comorbidity for all patients. Additionally, different ‘T subscores’ of the questionnaire were compared between the CAN group and Non-CAN group.
Results
A statistically significant difference between the CAN group and Non-CAN group for the T subscore ‘energy and fatigue’ (p = .004) was found, with the CAN group scoring higher. However, for the ‘overall T score’ between the two groups there was no statically significant difference (p = .11). Additionally, a significant negative correlation between ‘overall T score’ and cannabis use disorder (p = .032) was found.
Significance
This study provides new data on association of quality of life in epilepsy with cannabis use and can serve as a foundation for larger future studies to better assess this association.
期刊介绍:
Epileptic Disorders is the leading forum where all experts and medical studentswho wish to improve their understanding of epilepsy and related disorders can share practical experiences surrounding diagnosis and care, natural history, and management of seizures.
Epileptic Disorders is the official E-journal of the International League Against Epilepsy for educational communication. As the journal celebrates its 20th anniversary, it will now be available only as an online version. Its mission is to create educational links between epileptologists and other health professionals in clinical practice and scientists or physicians in research-based institutions. This change is accompanied by an increase in the number of issues per year, from 4 to 6, to ensure regular diffusion of recently published material (high quality Review and Seminar in Epileptology papers; Original Research articles or Case reports of educational value; MultiMedia Teaching Material), to serve the global medical community that cares for those affected by epilepsy.